| Mammography Center Of Monterey | |
|
700 Cass St Suite #120 Monterey CA 93940-2916 | |
| (831) 373-8932 | |
| (831) 373-5465 |
| Full Name | Mammography Center Of Monterey |
|---|---|
| Speciality | Clinic/Center |
| Location | 700 Cass St, Monterey, California |
| Authorized Official Name and Position | Mary Lou Catania (PRESIDENT) |
| Authorized Official Contact | 8313738932 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Mammography Center Of Monterey 700 Cass St Suite 120 Monterey CA 93940-2916 Ph: (831) 373-8932 | Mammography Center Of Monterey 700 Cass St Suite #120 Monterey CA 93940-2916 Ph: (831) 373-8932 |
| NPI Number | 1033202072 |
|---|---|
| Provider Enumeration Date | 10/02/2006 |
| Last Update Date | 09/03/2009 |
| Medicare PECOS PAC ID | 6002853363 |
|---|---|
| Medicare Enrollment ID | O20050408000703 |
News Archive
Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.
eCareSoft's eCS has received Complete Inpatient EHR Certification deeming the electronic health record (EHR) software capable of enabling hospitals and their affiliates to meet the Stage 1 meaningful use measures required to qualify for funding under the American Recovery and Reinvestment Act (ARRA).
A painful and debilitating condition that affects patients with kidney failure may be more common than previously believed and appears to be strongly associated with prior exposure to certain contrast agents used in imaging studies.
A team of Mass Eye and Ear Scientists led by Albert Edge, PhD, working with research fellow Yushi Hayashi, MD, PhD, has identified the mechanism that can lead to deafness in the rare syndrome, Norrie disease.
The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken.
› Verified 7 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033202072 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261Q00000X | Clinic/center | 43703 (California) | Primary |
| Provider Name | Kenneth E Averill |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1538182712 PECOS PAC ID: 3476544453 Enrollment ID: I20051020000572 |
News Archive
Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.
eCareSoft's eCS has received Complete Inpatient EHR Certification deeming the electronic health record (EHR) software capable of enabling hospitals and their affiliates to meet the Stage 1 meaningful use measures required to qualify for funding under the American Recovery and Reinvestment Act (ARRA).
A painful and debilitating condition that affects patients with kidney failure may be more common than previously believed and appears to be strongly associated with prior exposure to certain contrast agents used in imaging studies.
A team of Mass Eye and Ear Scientists led by Albert Edge, PhD, working with research fellow Yushi Hayashi, MD, PhD, has identified the mechanism that can lead to deafness in the rare syndrome, Norrie disease.
The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken.
› Verified 7 days ago
| Provider Name | Jennifer C Lin |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1194935932 PECOS PAC ID: 3678638590 Enrollment ID: I20090210000256 |
News Archive
Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.
eCareSoft's eCS has received Complete Inpatient EHR Certification deeming the electronic health record (EHR) software capable of enabling hospitals and their affiliates to meet the Stage 1 meaningful use measures required to qualify for funding under the American Recovery and Reinvestment Act (ARRA).
A painful and debilitating condition that affects patients with kidney failure may be more common than previously believed and appears to be strongly associated with prior exposure to certain contrast agents used in imaging studies.
A team of Mass Eye and Ear Scientists led by Albert Edge, PhD, working with research fellow Yushi Hayashi, MD, PhD, has identified the mechanism that can lead to deafness in the rare syndrome, Norrie disease.
The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken.
› Verified 7 days ago
| Provider Name | Melissa J Gerlach |
|---|---|
| Provider Type | Practitioner - Diagnostic Radiology |
| Provider Identifiers | NPI Number: 1639356553 PECOS PAC ID: 1456422450 Enrollment ID: I20090828000097 |
News Archive
Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.
eCareSoft's eCS has received Complete Inpatient EHR Certification deeming the electronic health record (EHR) software capable of enabling hospitals and their affiliates to meet the Stage 1 meaningful use measures required to qualify for funding under the American Recovery and Reinvestment Act (ARRA).
A painful and debilitating condition that affects patients with kidney failure may be more common than previously believed and appears to be strongly associated with prior exposure to certain contrast agents used in imaging studies.
A team of Mass Eye and Ear Scientists led by Albert Edge, PhD, working with research fellow Yushi Hayashi, MD, PhD, has identified the mechanism that can lead to deafness in the rare syndrome, Norrie disease.
The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken.
› Verified 7 days ago
News Archive
Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.
eCareSoft's eCS has received Complete Inpatient EHR Certification deeming the electronic health record (EHR) software capable of enabling hospitals and their affiliates to meet the Stage 1 meaningful use measures required to qualify for funding under the American Recovery and Reinvestment Act (ARRA).
A painful and debilitating condition that affects patients with kidney failure may be more common than previously believed and appears to be strongly associated with prior exposure to certain contrast agents used in imaging studies.
A team of Mass Eye and Ear Scientists led by Albert Edge, PhD, working with research fellow Yushi Hayashi, MD, PhD, has identified the mechanism that can lead to deafness in the rare syndrome, Norrie disease.
The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken.
› Verified 7 days ago
Monterey Bay Independent Physician Association, Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 40 Ryan Ct, Monterey, CA 93940 Phone: 650-358-3114 Fax: 650-358-5706 | |
Monterey Hospitalist Medical Group Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 23625 Holman Hwy, Monterey, CA 93940 Phone: 831-622-2708 Fax: 831-622-2709 | |
Evangelina E Martinez Md Inc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2 Upper Ragsdale Dr Ste B200, Monterey, CA 93940 Phone: 831-375-6334 Fax: 831-375-6331 | |
King Jang & Straface Mds Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 757 Pacific St, D2 D3, Monterey, CA 93940 Phone: 831-372-7374 | |
Ariamed Monterey Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 10 Harris Ct Ste A1, Monterey, CA 93940 Phone: 831-900-5115 | |
Gregory Sholeff Md Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 50 Ragsdale Dr Ste 120, Monterey, CA 93940 Phone: 831-375-8824 Fax: 831-375-8804 |